Thrombembolic events in patients with non-hodgkin's lymphoma And anticardiolipin antibodies

Abstract

Patients with non-Hodgkin's lymphoma (NHL) have an increased risk of thromboembolic events. It is important to identify NHL patients at increased risk of developing thromboembolic complications in order to apply prophylactic treatment. Anticardiolipin antibodies are autoantibodies that mistakenly target the body's own cardiolipins on the outside of cell membranes and platelets. The purpose of the article. Case detection of thrombembolic events in patients with non-Hodgkin's lymphoma and anticardiolipin antibodies (aCL). Materials and methods. The study included 47 patients with NHL in accordance with the International Histological and Cytological Classification of Tumors of Hematopoietic and Lymphatic Tissue proposed by the WHO (2016). Patients being complexly investigated, including the study of antibodies to aCL IgG, IgM, anti-β2-glycoprotein I IgG, IgM by the ELISA method and lupus anticoagulant by the Turbidimetry method. Results. Anticardiolipin antibodies were found in 7 patients (14.9%) with B-cell NHL. Venous thromboembolism was found in 2 patients (28.5%) with Mantle cell lymphoma and Small lymphocytic lymphoma, men, mean age of 70.5 years old. In both cases advanced stages of the disease have been found (III and IV, respectively) without signs of general intoxication B. The primary tumor focus was detected in the abdominal lymph nodes. Lupus anticoagulant was appreciated in both patients as opposed to antibodies to aCL IgG, IgM, anti-β2-glycoprotein I IgG, IgM. Conclusion. The presence of lupus anticoagulant, advanced age and stage in 28.5% of cases are risk factors for the development of thromboembolic complications in patients with NHL. Keywords: anticardiolipin antibodies, thrombosis, non-Hodgkin's lymphoma.